According to emerging studies, the excessive activation of microglia and the subsequent
release of pro-inflammatory cytokines play important roles in the pathogenesis and …

Parkinson's disease (PD) is one of the most common neurodegenerative disorders with a
global burden of approximately 6.1 million patients. Alpha-synuclein has been linked to both …

Alpha-synuclein is a protein implicated in Parkinson's disease and thought to be one of the
main pathological drivers in the disease, although it remains unclear how this protein elicits …

Following Alzheimer's, Parkinson's disease (PD) is the second-most common
neurodegenerative disorder, sharing an unclear pathophysiology, a multifactorial profile …

Existing therapeutic strategies for managing Parkinson disease (PD), which focus on
addressing the loss of dopamine and dopaminergic function linked with degeneration of …

Protein misfolding is a general hallmark of protein deposition diseases, such as Alzheimer's
disease or Parkinson's disease, in which different types of aggregated species (oligomers …

Parkinson's disease (PD) is the second most common neurodegenerative disorder and the
fastest growing neurologic disease in the world, yet no disease-modifying therapy is …

Parkinson disease is the second-most common neurodegenerative disorder that affects 2–
3% of the population≥ 65 years of age. Neuronal loss in the substantia nigra, which causes …

Parkinson's disease is the second most common neurodegenerative disorder. Although the
pathogenesis of Parkinson's disease is not entirely clear, the aberrant aggregation of α …

α-Synuclein (α-Syn) aggregation, proceeding from oligomers to fibrils, is one central
hallmark of neurodegeneration in synucleinopathies. α-Syn oligomers are toxic by triggering …